@article{ACS17463,
author = {Vyanne Hei Tung Chan and Krissada Meemook and Ching-Wei Lee and Angel Lai and Chun-Chin Chang and Tawai Ngernsritrakul and Surakiat Leelasithorn and Kevin Ka-Ho Kam and Bryan P. Yan and Alex Pui-Wai Lee and Gilbert H. L. Tang and Yat-Yin Lam and Adam S. H. Sung and Kent Chak-Yu So},
title = {Features and short-term outcomes of real-world transcatheter tricuspid valve repair vs. replacement in Asia-Pacific},
journal = {Annals of Cardiothoracic Surgery},
volume = {15},
number = {2},
year = {2026},
keywords = {},
abstract = {Background: Transcatheter therapies for tricuspid regurgitation (TR), including tricuspid transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR), have shown promising safety and efficacy in clinical trials. However, real-world data in the Asia-Pacific (APAC) region remain limited. This descriptive study evaluates the clinical characteristics, procedural details, and 30-day outcomes of T-TEER and TTVR in patients with severe TR in the APAC region.
Methods: A retrospective analysis was conducted on 174 patients with severe symptomatic TR treated between 2017 and 2025 at four centers in Hong Kong, Taiwan, and Thailand. Patients underwent T-TEER or TTVR (heterotopic or orthotopic). The primary outcome was TR reduction to ≤ moderate at 30 days. Secondary outcomes included procedural complications, adverse events, reinterventions, and symptom improvement.
Results: Of the total cohort, 136 patients underwent T-TEER and 38 underwent TTVR. The TTVR group had more severe TR [median effective regurgitant orifice (ERO) area: 0.85 vs. 0.57 cm2, P=0.001], a larger coaptation gap (median: 9.7 vs. 4.7 mm, P},
issn = {2304-1021}, url = {https://www.annalscts.com/article/view/17463}
}